Skip to content
MOTION FOR A RESOLUTION (D099729/02 – 2024/2841(RSP))

On the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified MON 94804, pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council

B-10-2024-0153

Committee on the Environment, Public Health and Food Safety · Rapporteur: Martin Häusling, Biljana Borzan, Anja Hazekamp

✦ In short · AI summary of this text, generated 4 Sept 2026

Written by a language model from the full text only; every figure comes from the text. The paragraph links open the paragraph a statement rests on — check the text itself before relying on it.

Parliament objects to the Commission's draft decision authorising genetically modified maize MON 94804, considering it exceeds implementing powers and is inconsistent with EU law. It calls on the Commission to withdraw the draft and submit a new one, and urges it to respect EU and international obligations, including sustainability and 'do no harm'.

Key points

  1. The GM maize is engineered to produce an artificial miRNA that suppresses genes in the gibberellic acid pathway, reducing plant height.
  2. Parliament notes insufficient data on miRNA interactions, persistence, and potential uptake from the gut, and on effects of reduced gibberellins on plant processes and stress responses.
  3. Member States raised critical comments on incomplete data and risks, including long-term stability of miRNA and gene transfer.
  4. The Commission has continued authorising GMOs despite Parliament's objections and lack of Member State support.
  5. Parliament considers the draft decision exceeds implementing powers and is incompatible with the aim of Regulation (EC) No 1829/2003.
  6. Calls on the Commission to withdraw the draft and submit a new one to the committee.
  7. Expresses disappointment that the Commission has continued authorising GMOs despite its recognition of sustainability needs.
  8. Urges the Commission to take into account international agreements and to accompany draft acts with an explanatory memorandum on 'do no harm'.

Who is affected

  • The Commission is called to withdraw its draft decision and submit a new one.
  • The applicant, Bayer, would be affected if authorisation is not granted.